Correlations between percentage changes in biomarker levels and improvement in swollen and tender joint counts and DAS28-CRP at Week 16.
| Biomarker | Treatment Group | Visit | Swollen Joint Count | Tender Joint Count | DAS28-CRP | DAS28-ESR |
|---|---|---|---|---|---|---|
| IL-18 | Golimumab plus MTX | Baseline | r = −0.178, p = 0.0410 | NS | NS | NS |
| Wk 4 | NS | NS | NS | NA | ||
| Wk 16 | NS | NS | NS | NS | ||
| Placebo plus MTX | Baseline | NS | NS | NS | NS | |
| Wk 4 | NS | NS | NS | NA | ||
| Wk 16 | NS | r = +0.465, p = 0.0126 | NS | r = −0.467, p = 0.0186 | ||
| SAA | Golimumab plus MTX | Baseline | NS | NS | r = +0.185, p = 0.0335 | NS |
| Wk 4 | NS | NS | r = +0.247, p = 0.0057 | NA | ||
| Wk 16 | r = −0.205, p = 0.0296 | NS | r = +0.219, p = 0.0206 | r = +0.258 p = 0.0059 | ||
| Placebo plus MTX | Baseline | NS | NS | r = +0.417, p = 0.0176 | NS | |
| Wk 4 | NS | NS | NS | NA | ||
| Wk 16 | NS | NS | NS | NS | ||
| E-selectin | Golimumab plus MTX | Baseline | NS | NS | NS | NS |
| Wk 4 | r = −0.212, p = 0.0177 | r = −0.192, p = 0.0317 | r = +0.341, p = 0.0001 | NA | ||
| Wk 16 | r = −0.216, p = 0.0218 | r = −0.230, p = 0.0144 | r = +0.306, p = 0.0010 | r = +0.301, p = 0.0012 | ||
| Placebo plus MTX | Baseline | NS | NS | NS | NS | |
| Wk 4 | NS | NS | NS | NA | ||
| Wk 16 | NS | NS | NS | NS | ||
| CRP | Golimumab plus MTX | Baseline | NS | NS | NA | r = +0.273, p = 0.0012 |
| Wk 4 | NS | r = −0.198, p = 0.0240 | NA | NA | ||
| Wk 16 | r = −0.204, p = 0.0272 | NS | NA | r = −0.257, p = 0.0056 | ||
| Placebo plus MTX | Baseline | NS | NS | NA | NS | |
| Wk 4 | r = −0.354, p = 0.0432 | NS | NA | NA | ||
| Wk 16 | NS | NS | NA | NS | ||
| MMP-9 | Golimumab plus MTX | Baseline | NS | NS | NS | NS |
| Wk 4 | NS | NS | r = +0.203, p = 0.0236 | NA | ||
| Wk 16 | NS | NS | NS | NS | ||
| Placebo plus MTX | Baseline | NS | NS | NS | NS | |
| Wk 4 | NS | NS | NS | NA | ||
| Wk 16 | NS | NS | NS | NS |
CRP: C-reactive protein; DAS28-CRP/ESR: disease activity score based on 28-joint count and incorporating CRP/ESR; IL-18: interleukin-18; MMP-9: matrix metalloproteinase 9; MTX: methotrexate; NA: not applicable/invalid because DAS28-CRP includes CRP in its calculation or because DAS28-ESR was not determined at Wk 4; NS: not significant; SAA: serum amyloid A.